Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Madeline Brendle"'
Publikováno v:
BMC Psychiatry, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a
Externí odkaz:
https://doaj.org/article/4c46d146471a4d64b0827ba3012461af
Autor:
Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich, Madeline Brendle, Claire Moore, Reid Robison
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
IntroductionA comorbid diagnosis of a depressive disorder is a negative prognostic factor for individuals with AN, and novel treatments are needed to target depressive symptoms in this population. One emerging promising treatment for depressive disor
Externí odkaz:
https://doaj.org/article/41b7076077a24ec5a682de45d0c4380d
Autor:
Reid Robison, Adele Lafrance, Madeline Brendle, Michelle Smith, Claire Moore, Sachin Ahuja, Scott Richards, Nicole Hawkins, Erin Strahan
Publikováno v:
Journal of Eating Disorders, Vol 10, Iss 1, Pp 1-9 (2022)
Abstract Background Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (
Externí odkaz:
https://doaj.org/article/79b0c9e0467a47a285172a47dfc5f786
Autor:
Blerida Banushi, Madeline Brendle, Anya Ragnhildstveit, Tara Murphy, Claire Moore, Johannes Egberts, Reid Robison
Publikováno v:
Brain Sciences, Vol 13, Iss 2, p 256 (2023)
Anxiety disorders are the most common group of mental disorders, but they are often underrecognized and undertreated in primary care. Dysfunctional breathing is a hallmark of anxiety disorders; however, mainstays of treatments do not tackle breathing
Externí odkaz:
https://doaj.org/article/e419c9e0377840388ee376d075bec4d9
Autor:
Anya Ragnhildstveit, Matthew Slayton, Laura Kate Jackson, Madeline Brendle, Sachin Ahuja, Willis Holle, Claire Moore, Kellie Sollars, Paul Seli, Reid Robison
Publikováno v:
Brain Sciences, Vol 12, Iss 3, p 382 (2022)
Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based tr
Externí odkaz:
https://doaj.org/article/54add4fcbe6546aab1ebf4a4741e3f8d
Autor:
Reid Robison, Madeline Brendle, Claire Moore, Hannah Cross, Lindsay Helm, Shannon Darling, Stephen Thayer, Paul Thielking, Scott Shannon
Publikováno v:
Journal of Psychoactive Drugs. :1-10
Autor:
Madeline Brendle, Anya Ragnhildstveit, Matthew Slayton, Leo Smart, Sarah Cunningham, Mackenzie H. Zimmerman, Paul Seli, Michael Santo Gaffrey, Lynnette Astrid Averill, Reid Robison
Publikováno v:
Journal of Psychedelic Studies. 6:176-187
Background and AimsKetamine and esketamine have garnered interest in both psychiatric research and clinical practice for treatment-resistant depression (TRD). In this review, we examined registered trials investigating the therapeutic use of ketamine
Autor:
Madeline Brendle, Sachin Ahuja, Maisa Della Valle, Claire Moore, Paul Thielking, Daniel C Malone, Reid Robison
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1323-1336
Aim: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray. Methods: This retrospective cohort study used data collected from a psychiatric clinic's EHR system. Results: A total o
Autor:
Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem
Publikováno v:
Blood. 140:5291-5292
Publikováno v:
Oncology Research and Treatment. 44:476-484
Objectives: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine monotherapy for pancreatic cancer (PC). It is still unclear which chemotherapy regimen is the most optima